Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs

Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs

Abstract Background Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs. Its use in combination with L‐asparaginase (L‐ASP) has not been studied. Hypothesis/Objectives To evaluate the...

Full description

Bibliographic Details
Main Authors: Jacob R. Cawley, Zachary M. Wright, Karri Meleo, Gerald S. Post, Craig A. Clifford, Kathryn R. Vickery, David M. Vail, Philip J. Bergman, Douglas H. Thamm
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Journal of Veterinary Internal Medicine
Subjects:
asparaginase
chemotherapy
dog
GS‐9219
guanine
lymphosarcoma
Online Access:https://doi.org/10.1111/jvim.15723

Internet

https://doi.org/10.1111/jvim.15723

Similar Items